Medicare Enrolled

Dr. Philip Ayvazian, MD

Urology Physician · Worcester, MA
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Low-engagement
33 KENDALL ST, Worcester, MA 01605
5083348765
In practice since 2005 (20 years)
NPI: 1487654984 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Ayvazian from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Ayvazian? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Ayvazian

Dr. Philip Ayvazian is an urology physician in Worcester, MA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Ayvazian performed 4,857 Medicare services across 3,098 unique beneficiaries.

Between the years covered by Open Payments, Dr. Ayvazian received a total of $4,083 from 40 pharmaceutical and/or device companies across 193 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in urology physician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Ayvazian is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ Top 22% volume in MA $4,083 industry payments

Medicare Practice Summary

Medicare Utilization ↗
4,857
Medicare services
Top 22% in MA for urology physician
3,098
Unique beneficiaries
$47
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~243 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Urinalysis with microscopic exam
A urine test performed manually that includes examining the sample under a microscope to check for abnormalities.
1,142 $3 $20
Creatinine test (kidney function)
A blood test that measures the amount of creatinine to assess kidney function or detect muscle injury.
1,140 $5 $25
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
1,118 $93 $250
Bladder ultrasound after voiding
An ultrasound scan performed after urination to measure the amount of urine remaining in the bladder.
455 $8 $65
Complete ultrasound of retroperitoneum
An ultrasound examination of the structures located behind the abdominal cavity.
250 $88 $340
Cystourethroscopy
A diagnostic exam of the bladder and urethra using an endoscope to visually inspect the urinary tract.
181 $200 $600
Imaging of urinary tract with contrast
An imaging test of the urinary tract performed after a contrast agent is injected to enhance visibility of the structures.
125 $20 $35
Leuprolide acetate (for depot suspension), 7.5 mg 114 $133 $502
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
67 $117 $390
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
55 $72 $175
Ureteral stent insertion via endoscope
A flexible tube is inserted into the ureter using an endoscope to keep the passage open and allow urine to flow from the kidney to the bladder.
38 $115 $625
Subcutaneous or intramuscular chemotherapy injection
This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle.
37 $28 $105
Prostate gland biopsy
A procedure to remove small samples of tissue from the prostate gland for laboratory examination.
22 $203 $525
Transrectal ultrasound of the pelvis
An ultrasound imaging procedure where a probe is inserted into the rectum to visualize pelvic structures.
22 $117 $362
Ultrasound guidance for needle placement
Use of ultrasound imaging to guide the precise placement of a needle during a medical procedure.
22 $49 $500
Electronic assessment of bladder emptying
A test that uses electronic monitoring to evaluate how well the bladder empties urine.
19 $6 $185
Endoscopic removal of foreign body, stone, or stent from urethra or bladder
A procedure to remove a foreign object, stone, or stent from the urethra or bladder using an endoscope. The endoscope is a thin tube with a camera inserted into the urinary tract to locate and extract the item.
18 $259 $688
Ureteral stone crushing with stent insertion
An endoscope is used to break up a stone in the ureter, followed by the placement of a stent to keep the ureter open.
16 $335 $1,200
Ultrasound of scrotum
An imaging test that uses sound waves to create pictures of the scrotum and its contents. It helps evaluate the testicles and surrounding structures.
16 $77 $300
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.5% high complexity
19.5% medium
79.0% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$4,083
Total received (2018-2024)
Avg $583/year across 7 years
Top 32% in MA for urology physician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
40
Companies
193
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,604 (88.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$478 (11.7%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$829
2023
$852
2022
$682
2021
$154
2020
$429
2019
$490
2018
$647

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Merck Sharp & Dohme LLC
$145
Janssen Biotech, Inc.
$125
Sumitomo Pharma America, Inc.
$92
Astellas Pharma US Inc
$88
Ferring Pharmaceuticals Inc.
$85
PFIZER INC.
$59
ABBVIE INC.
$55
UROGEN PHARMA, INC.
$42
ConvaTec Inc.
$41
Bayer Healthcare Pharmaceuticals Inc.
$29
Axonics, Inc.
$25
PROGENICS PHARMACEUTICALS, INC.
$23
Myriad Genetic Laboratories, Inc.
$19
Top 3 companies account for 43.7% of 2024 payments
All-time payments by company (2018-2024) ›
Astellas Pharma US Inc
$963
Janssen Biotech, Inc.
$334
PFIZER INC.
$322
Merck Sharp & Dohme LLC
$293
Endo Pharmaceuticals Inc.
$194
Sumitomo Pharma America, Inc.
$175
Bayer Healthcare Pharmaceuticals Inc.
$162
PROCEPT BioRobotics Corporation
$119
AbbVie Inc.
$114
Ferring Pharmaceuticals Inc.
$113
AbbVie, Inc.
$101
ABBVIE INC.
$91
ConvaTec Inc.
$88
Axonics, Inc.
$71
Avadel Specialty Pharmaceuticals, LLC
$67
Merck Sharp & Dohme Corporation
$61
Myriad Genetic Laboratories, Inc.
$60
Boston Scientific Corporation
$55
Teleflex LLC
$53
Bayer HealthCare Pharmaceuticals Inc.
$49
Accord Healthcare, Inc.
$47
Myovant Sciences Inc.
$47
Novartis Pharmaceuticals Corporation
$47
Rochester Medical Corporation
$43
UROGEN PHARMA, INC.
$42
Progenics Pharmaceuticals, Inc.
$40
Acerus Pharmaceuticals Corporation
$39
Coloplast Corp
$33
180 Medical, Inc.
$29
Otsuka America Pharmaceutical, Inc.
$27
Supernus Pharmaceuticals, Inc.
$27
Blue Earth Diagnostics Limited
$24
PROGENICS PHARMACEUTICALS, INC.
$23
TOLMAR Pharmaceuticals, Inc.
$21
Aytu BioScience, Inc
$20
UROVANT SCIENCES INC
$19
Antares Pharma, Inc.
$18
Mission Pharmacal Company
$18
Dendreon Pharmaceuticals LLC
$17
Kowa Pharmaceuticals America, Inc.
$16
Top 3 companies account for 39.7% of all-time payments
Associated products mentioned in payments ›
ADSTILADRIN · AFINITOR · AQUABEAM ROBOTIC SYSTEM · AVEED · Androgel · Axumin · BOTOX · BRIDION · Bulkamid · CAMCEVI · CONTINENCE CARE · CURE CATHETER · EDEX · ELIGARD · ERLEADA · Erleada · FIRMAGON · GEMTESA · GENERAL BPH · GENTLECATH · JELMYTO · JYNARQUE · KEYTRUDA · LUPRON DEPOT · Lithostat · Lupron · Lupron Depot · MAGIC3 · MYRBETRIQ · Myrbetriq · NOCDURNA · Natesto · Noctiva · Nubeqa · ORGOVYX · PLUVICTO · PROLARIS · PROVENGE · PYLARIFY · Rezum Generator · SEGLENTIS · SPEEDICATH · TOVIAZ · UROLIFT · XIAFLEX · XTANDI · XYOSTED · Xtandi · rezum Generator
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (88%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for an urology physician in Worcester?
Compare urology physicians in the Worcester area by procedure volume, costs, and industry payment transparency.
Browse urology physicians nearby

Geographic Context

Urology physicians within 10 mi
41
Per 100K population
4.8
County median income
$93,561
Nearest hospital
ADCARE HOSPITAL OF WORCESTER INC
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Ayvazian is a clinical cardiology specialist, with above-average Medicare volume (top 22% in MA), with low-engagement industry engagement, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Ayvazian experienced with urinalysis with microscopic exam?
Based on Medicare claims data, Dr. Ayvazian performed 1,142 urinalysis with microscopic exam services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Ayvazian receive payments from pharmaceutical companies?
Yes. Dr. Ayvazian received a total of $4,083 from 40 companies across 193 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Ayvazian's costs compare to other urology physicians in Worcester?
Dr. Ayvazian's average Medicare payment per service is $47. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Ayvazian) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →